Clinical Trial Update: A Phase 3 Study to Compare Upadacitinib to Abatacept in Subjects With Rheumatoid Arthritis on Stable Dose of Conventional Synthetic Disease- Modifying Antirheumatic Drugs (csDMARDs) Who Have an Inadequate Response or Intolerance to Biologic DMARDs [Phase 3]

View source ↗

Summary

Phase 3 trial comparing upadacitinib to abatacept in rheumatoid arthritis patients on csDMARDs with inadequate response or intolerance to biologic DMARDs has co…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Rheumatoid Arthritis

Drugs mentioned

• ORENCIA (ABATACEPT)
• RINVOQ (Upadacitinib)

Snippet

Sponsor: AbbVie | Conditions: Rheumatoid Arthritis (RA) | Phase 3 | Status: COMPLETED | Results posted: 2020-06-04